New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia ...Middle East

RARITAN, N.J., Dec. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from pooled analyses of long-term follow-up from multiple clinical trials evaluating the use of IMBRUVICA® (ibrutinib) monotherapy and in combination as first-line...

Hence then, the article about new data demonstrate long term benefit of imbruvica ibrutinib as first line treatment for high risk chronic lymphocytic leukemia was published today ( Sunday 06/12/2020 - 09:48 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia )

Also on site :

• Retired Gen. Wesley Clark tangled up in a crypto fraud suit with Burning Man buddies
• My Friend Invited Us for Dinner. When She Greeted Us at the Door, She Asked for Something Shocking.
• Iconic '80s Boy Band Impresses With 'Amazing' Live Performance